Markets:

Overview

News

Currencies

International

Treasuries

Repligen Corporation - Common Stock (NQ:RGEN)

136.04 -0.40 (-0.29%)

Streaming Delayed Price Updated: 1:59 PM EST, Feb 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Repligen Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

3 Volatile Stocks Walking a Fine Line

February 02, 2026

Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced...

Via StockStory

2 Cash-Producing Stocks to Target This Week and 1 We Ignore

January 28, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

3 Reasons to Sell RGEN and 1 Stock to Buy Instead

January 26, 2026

Repligen has had an impressive run over the past six months as its shares have beaten the S&P 500 by 28.3%. The stock now trades at $163.29, marking a 36.5% gain. This was partly due to its solid...

Via StockStory

Topics Stocks

3 High-Flying Stocks That Fall Short

January 18, 2026

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices,...

Via StockStory

Earnings Scheduled For October 28, 2025 ↗

October 28, 2025

Via Benzinga

Why Repligen (RGEN) Shares Are Sliding Today

January 14, 2026

Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 3.9% in the afternoon session after the company presented at the JPMorgan Healthcare Conference and shared its sales...

Via StockStory

Topics Artificial Intelligence

1 Cash-Heavy Stock to Target This Week and 2 Facing Challenges

January 05, 2026

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Via StockStory

1 Volatile Stock to Target This Week and 2 We Turn Down

December 07, 2025

Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor...

Via StockStory

Why Repligen (RGEN) Stock Is Trading Up Today

November 21, 2025

Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 5.7% in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate...

Via StockStory

Topics Artificial Intelligence Economy Stocks

Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know

November 11, 2025

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid...

Via StockStory

Topics Artificial Intelligence Stocks

3 Cash-Producing Stocks We Approach with Caution

November 10, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

Drug Development Inputs & Services Stocks Q3 Recap: Benchmarking Repligen (NASDAQ:RGEN)

November 06, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Repligen (NASDAQ:RGEN) and its peers.

Via StockStory

5 Revealing Analyst Questions From Repligen’s Q3 Earnings Call

November 04, 2025

Repligen’s third quarter saw revenue and non-GAAP profit exceed Wall Street expectations, yet the market responded negatively. Management attributed the quarter’s strong top-line performance to...

Via StockStory

Topics Earnings

3 Hyped Up Stocks with Open Questions

October 30, 2025

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial...

Via StockStory

RGEN Q3 Deep Dive: Robust Product Demand Offset by Margin Pressures and Guidance Reset

October 29, 2025

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) announced better-than-expected revenue in Q3 CY2025, with sales up 21.9% year on year to $188.8 million. The company’s full-year...

Via StockStory

Why Repligen (RGEN) Shares Are Trading Lower Today

October 28, 2025

Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 4.2% in the afternoon session after the company reported third-quarter results that beat revenue and profit...

Via StockStory

Topics Economy Government World Trade

Repligen Corp (NASDAQ:RGEN) Posts Strong Q3 2025 Results, Beating Revenue and EPS Estimates ↗

October 28, 2025

Repligen's Q3 2025 results beat earnings and revenue estimates, driving a positive market reaction and raising full-year guidance.

Via Chartmill

Repligen’s (NASDAQ:RGEN) Q3 Sales Beat Estimates

October 28, 2025

Via StockStory

Topics Earnings

Repligen Earnings: What To Look For From RGEN

October 26, 2025

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting results this Tuesday before market hours. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence

3 Inflated Stocks with Questionable Fundamentals

October 21, 2025

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro...

Via StockStory

Federal Reserve Signals Further Rate Cuts Amidst Worsening Labor Market and Divided Opinions

October 14, 2025

Washington D.C. – The Federal Reserve has sent clear signals of a continued dovish pivot, with Chair Jerome Powell indicating the likelihood of two additional quarter-point interest rate cuts before...

Via MarketMinute

Topics Artificial Intelligence Bonds Credit Cards

Myriad Genetics, Omnicell, Globus Medical, Repligen, and Teleflex Stocks Trade Down, What You Need To Know

October 10, 2025

A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.

Via StockStory

Topics Economy Government World Trade

Thermo Fisher Scientific Soars on Strategic Wins, Market Optimism

October 01, 2025

Thermo Fisher Scientific Inc. (NYSE: TMO) experienced a robust surge in its stock value today, October 1, 2025, climbing an impressive 9.79% as market optimism swelled around a series of recent...

Via MarketMinute

Topics Artificial Intelligence Economy Government

What 8 Analyst Ratings Have To Say About Repligen ↗

October 01, 2025

Via Benzinga

Why Is Repligen (RGEN) Stock Soaring Today

October 01, 2025

Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 6.6% in the afternoon session after HSBC initiated coverage on the stock with a 'Buy' rating and a $150 price...

Via StockStory

Topics Government

Repligen, BrightSpring Health Services, Danaher, Thermo Fisher, and Amgen Shares Skyrocket, What You Need To Know

September 30, 2025

A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.

Via StockStory

Topics Government

1 Volatile Stock to Target This Week and 2 Facing Challenges

September 25, 2025

Via StockStory

3 Reasons to Sell RGEN and 1 Stock to Buy Instead

September 24, 2025

Over the past six months, Repligen’s shares (currently trading at $123.26) have posted a disappointing 15.1% loss, well below the S&P 500’s 15.5% gain. This might have investors contemplating their...

Via StockStory

Topics Stocks

Drug Development Inputs & Services Stocks Q2 Results: Benchmarking Repligen (NASDAQ:RGEN)

September 22, 2025

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Repligen (NASDAQ:RGEN) and its peers.

Via StockStory

This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

September 22, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.